psma pet ratio predicts response to [177lu]psma radioligand therapy: a multicenter study
Published 1 year ago • 103 plays • Length 2:56Download video MP4
Download video MP3
Similar videos
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
1:11
recip: a novel framework for treatment response evaluation using psma-pet/ct in patients with mcrpc
-
15:35
lu-psma radioligand therapy
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022
-
1:50
cat 3: psma radioligand therapy (prlt) of end-stage prostate cancer patients selected by psma pet/ct
-
4:09
psma pet-ct scan and treatments for patients with cn1 prostate cancer
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
3:50
the role of psma pet in recurrent prostate cancer
-
4:28
upfront [177lu]lu-psma-617 radioligand therapy prior to radical prostatectomy in men with hr pc
-
17:58
how to integrate psma pet findings into treatment algorithms
-
4:11
validation of psma-pet to the most used nomograms for pelvic lymph-node metastases prediction
-
3:42
unanswered questions for the use of psma pet in the staging of prostate cancer
-
10:55
psma pet/ct imaging | appropriate use criteria | snmmi
-
0:17
#psma #pet for bcr salvage #radiotherapy #cancer #prostate #cancer
-
4:24
psma after recurrence, and psma specificity | answering youtube comments #26 | mark scholz, md
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
4:47
advances in psma radioligand therapy for mcrpc
-
0:44
remaining questions regarding psma radioligand therapies